NVS•benzinga•
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
Summary
FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 3, 2025 by benzinga